Gene Editing Enables Type 1 Diabetes Patient to Produce Insulin

Key Takeaways

1. A 42-year-old man with type 1 diabetes received a transplant of genetically altered islet cells without immunosuppressive drugs.
2. The research utilized CRISPR-Cas12b gene editing to make islet cells immune to the patient’s immune response.
3. The modified cells survived in the patient’s body while non-modified cells were destroyed by the immune system.
4. The transplanted cells successfully produced insulin over a 12-week observation period.
5. This study offers promising prospects for a new treatment approach for type 1 diabetes, potentially reducing reliance on insulin injections and immunosuppressive medications.

In a significant advancement in the field of medicine, a 42-year-old man who has struggled with type 1 diabetes for 37 years received a transplant of genetically altered islet cells from a 60-year-old donor. Remarkably, this was done without any immunosuppressive drugs. The findings, featured in a publication by the New England Journal of Medicine, outline a new method that might eventually lead to a cure for this chronic condition.

Innovative Gene Editing Techniques

Before the trial commenced, the patient had an insulin production level that was “undetectable.” The research team utilized CRISPR-Cas12b gene editing to make these islet cells immune to the patient’s own immune response. This involved removing HLA proteins, which serve as markers that the immune system recognizes as foreign, and then incorporating CD47, a protein that signals the immune system to not attack these cells. Over the course of 17 injections, the doctors introduced approximately 80 million modified cells into the patient’s body.

Successful Survival of Cells

To observe the effects, the researchers also included a mix of fully and partially edited cells. The patient’s immune system quickly targeted and destroyed these non-modified cells. However, the hypoimmune cells were completely overlooked by the immune system, allowing them to survive and produce insulin throughout the 12-week observation period.

Measurements of C-peptide during the study confirmed that the islet cells were integrated successfully and capable of producing insulin. Although this is a preliminary proof-of-concept study, it brings promising prospects for a new approach to treating type 1 diabetes, potentially freeing patients from the need for constant insulin injections and the negative side effects associated with immunosuppressive medications.

Source:
Link